Literature DB >> 16572069

Preoperative prognostic factors for pN2 non-small cell lung cancer.

Masaki Tomita1, Yasunori Matsuzaki, Tetsuya Shimizu, Masaki Hara, Takanori Ayabe, Toshio Onitsuka.   

Abstract

PURPOSE: The prognosis of non-small cell lung cancer (NSCLC) with pathologic mediastinal lymph node involvement (pN2) is poor in general. The majority of previously reported prognostic factors of pN2 disease are not available preoperatively. When we perform preoperative induction chemotherapy, we should undertake therapeutic planning according to preoperative factors.
METHODS: We focused on preoperative clinicopathologic factors, and investigated the prognosis in 78 patients with pN2 NSCLC who received complete resection.
RESULTS: Age, gender, histologic subtype, tumor location, smoking status and cT status were not related to patients' survival. On the other hand patients with cN0 disease and normal serum carcinoembryonic antigen (CEA) level had a significant favorable survival (p = 0.038 and p = 0.019, respectively). In addition, comorbidity had a significant survival impact (p = 0.031). Despite there being no independent prognostic factors by multivariate analysis, the patients without all of cN1-2 disease, elevated serum CEA level and comorbidity had a significant favorable prognosis (p = 0.008).
CONCLUSION: Among the preoperative factors examined, pN2 patients with all cN0 disease, normal serum CEA level and no comorbidities might have a favorable prognosis. Combined use of these might be a useful prognostic determinant, and even in the presence of pN2 disease, patients without these unfavorable 3 factors might have a favorable prognosis when treated with surgery alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572069

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  1 in total

1.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.